Opipramol
Izgled
(IUPAC) ime | |||
---|---|---|---|
4-[3-(5H-dibenz[b,f]azepin- 5-yl)propyl]-1-piperazinethanol | |||
Klinički podaci | |||
Identifikatori | |||
CAS broj | 315-72-0 | ||
ATC kod | N06AA05 | ||
PubChem[1][2] | 9417 | ||
ChemSpider[3] | 9046 | ||
KEGG[4] | D08297 | ||
ChEMBL[5] | CHEMBL370753 | ||
Hemijski podaci | |||
Formula | C23H29N3O | ||
Mol. masa | 363.496 g/mol | ||
SMILES | eMolekuli & PubHem | ||
| |||
Farmakoinformacioni podaci | |||
Trudnoća | ? | ||
Pravni status | ℞ Prescription only | ||
Način primene | Oral |
Opipramol (Insidon, Pramolan, Ensidon, Oprimol) je antidepresiv i anksiolitik koji se koristi u nizu Evropskih zemalja.[6][7] Mada je on član porodice tricikličnih antidepresanata, primarni mehanizam dejstva se znatno razlikuje.[7] On nije inhibitor preuzimanja nego deluje kao agonist sigma receptora, pored drugih osovina.[7]
Opipramol se tipično koristi u lečenju generalizovanog anksioznog poremećaja.[6] Njegovo dejstvo postaje uočljivo nakon 1-2 nedelje hronične upotrebe. Na početku primene, opipramol ima znatno sedativno dejstvo usled njegovih antihistaminskih osobina, ali taj efekat postaje manje promenentan sa vremenom.
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.
- ↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ 6,0 6,1 Möller HJ, Volz HP, Reimann IW, Stoll KD (February 2001). „Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group”. Journal of Clinical Psychopharmacology 21 (1): 59–65. DOI:10.1097/00004714-200102000-00011. PMID 11199949.
- ↑ 7,0 7,1 7,2 Müller WE, Siebert B, Holoubek G, Gentsch C (November 2004). „Neuropharmacology of the anxiolytic drug opipramol, a sigma site ligand”. Pharmacopsychiatry 37 Suppl 3: S189–97. DOI:10.1055/s-2004-832677. PMID 15547785.